Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10p -0.12% 84.00p 83.95p 84.30p 85.20p 83.30p 83.40p 1,778,041 16:29:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 1.3 -0.7 -0.1 - 694.68

Woodford Patient Capital (WPCT) Latest News (1)

More Woodford Patient Capital News
Woodford Patient Capital Takeover Rumours

Woodford Patient Capital (WPCT) Share Charts

1 Year Woodford Patient Capital Chart

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Woodford Patient Capital (WPCT) Discussions and Chat

Woodford Patient Capital Forums and Chat

Date Time Title Posts
22/11/201715:44::: WOODFORD PATIENT CAPITAL TRUST :::1,300
21/11/201709:34Woodford Patient Capital Trust128

Add a New Thread

Woodford Patient Capital (WPCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-22 17:15:0086.15616,000530,684.00O
2017-11-22 17:15:0083.01420,108348,731.65O
2017-11-22 16:48:5284.1929,48524,821.95O
2017-11-22 16:35:1684.0051,77343,489.32UT
2017-11-22 16:29:4784.00254213.36AT
View all Woodford Patient Capital trades in real-time

Woodford Patient Capital (WPCT) Top Chat Posts

DateSubject
22/11/2017
08:20
Woodford Patient Capital Daily Update: Woodford Patient Capital Trust is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker WPCT. The last closing price for Woodford Patient Capital was 84.10p.
Woodford Patient Capital Trust has a 4 week average price of 83.25p and a 12 week average price of 83.25p.
The 1 year high share price is 106.50p while the 1 year low share price is currently 83.25p.
There are currently 827,000,000 shares in issue and the average daily traded volume is 2,181,712 shares. The market capitalisation of Woodford Patient Capital Trust is £694,680,000.
16/11/2017
11:50
andyj: And now 95p, latest NAV 94.5p. The discount is narrowing and becoming harder to justify unless the share price falls further.
12/11/2017
17:42
the air marshall: Pug, you've got a cheek. You and your buddy, I seem to remember, were lambasting WPCT for owning Provident Financial when it tanked (and which you didn't predict). Provident Financial is NOT a WPCT share nor has it ever been. riskversusreward has a record as long as your arm for doing the same thing with a long list of shares. Neither of you has apologised! As for Sphere, I never said that it wasn't in WPCT. What I do resent, however, is you and your fellow troll coming out as ruminative experts on Sphere, which anyway makes up only 0.01 of WPCT. Neither of you know anything important about the non-quoted shares and therefore your so-called arguments on those that form a large part of WPCT are completely spurious.
09/11/2017
09:01
mazarin: Kerrisdale's report has to be taken into context as it has a short position in Prothena Corporation PLC and stands to benefit if its share price falls. Their full report can be found at hxxp://kerr.co/prta.
07/11/2017
21:22
riverman77: I note that Purplebricks has been strong over past few days so maybe that's lifted sentiment. As you suggest, the rise in WPCT price is almost entirely due to a narrowing of the discount, so no meaningful nav growth to get excited about just yet.
04/11/2017
09:23
mazarin: For no apparent reason, I can think of things have slightly turned around here lately and an article this week end, comments on the relative poor performance of WPTC and other managed funds. Here's an extract: "......Over the summer months Woodford suffered one stock disaster after another, as shares in Provident Financial (PFG), AstraZeneca (AZN), Allied Mines (ALM) and AA (AA.) all fell sharply for various reasons. Some falls followed profits warnings and could have been anticipated, but others - such as the fall in the AA's share price triggered by the firm's executive chairman being sacked for gross misconduct - could not have been foreseen. Rather than hide, Woodford confronted his critics and issued an apology for his fund's poor performance. Reassuring investors, he said: "[While] the short-term performance is painful and difficult, it isn't a permanent loss of capital. And I can, and I believe I will, rebuild the performance and rebuild that capital that we've lost recently." Fund analysts have overwhelmingly backed Woodford, insisting that he has not become a bad fund manager overnight. Tom Becket, chief investment officer at wealth manager Psigma, points out that Woodford has tended to run 'hot and cold' over his career, but over the long run he has outperformed the FTSE All-Share index (ASX) by a considerable margin. He says: "When a fund manager is out of form, an investor's natural reaction is to sell, but they should really be doing the opposite, as peak negativity around a fund manager can be a sign that they are about to start outperforming again......." For the full article, see : http://tinyurl.com/y9kce835
24/8/2017
12:58
the air marshall: I'm really feeling rather happy. When trolls like LK and Plug were merrily crowing over some minor blip or other in the share price of some other investments not so long ago, I went out and bought a large lump of WPCT. Those shares are now showing a gratifying profit. I don't feel inclined to liquidate at the moment. The trolls are not sufficiently intelligent to realise that making mindless 'sky is falling' posts is not the name of the game. The whole point is to buy low and sell high. You're actually allowed to make money. From his posts I deduce that LK (and a few recent posters here) has got it the wrong way round. Anybody can see from his garbled unintelligible posts that he could never actually have made a real profit. He's always advocating that people sell when the shares are low:
04/8/2017
11:24
mad foetus: What does "10 years of growth to achieve its existing valuation mean"? Where are these rules written down?I don't much like PURP, but it is a disruptive company, and all that matters is its share price and the willingness of the market to believe that it will be able to generate profits in future.Or to ask the question the other way around, at what time since it was launched would you have bought shares in Amazon? Or would you have stood by, saying it was overvalued, while it 100 bagged?The only rule in investing is to make money.
20/7/2017
08:58
jonwig: mazarin - how the NAV is arrived at is here, From post #1013: There are strict rules for valuing unquoted companies: Http://www.privateequityvaluation.com/download/i/mark_dl/u/4012990401/4625734325/151222%20IPEV%20Valuation%20Guidelines%20December%202015%20Final.pdf Valuation guidelines, p11. I don't see the point of spending money on a daily NAV when so much of the portfolio is unquoted. As for how the share price is determined, it's quite simply supply and demand with trades going through market makers*. I suspect there will soon be selling by frustrated holders who bought in the 2015 gold rush and want rid. If I actually knew what moved share prices, I'd be rather richer than I am. *EDIT: it's actually traded on SETS too, though not many participants it seems.
30/4/2017
19:18
topvest: I think its the wrong time in the economic cycle to be buying this trust. This stock (as all the US tech bubble stocks) will get hammered when the next downturn comes. Best time to buy this is at an equivalent time to March 2009, albeit hopefully nothing as deep as the last recession. What struck me in the latest annual report is the £75m overdraft. This is a strategic error in my book as such debt is only really advisable when you have a liquid portfolio. Lets say that the share price drops 50% on a stock market bear phase. If NAV drops to 60p and share price to 45p they are going to be forced sellers on their illiquid portfolio to avoid a covenant issue. That would be a disaster. Why take that risk at this point in the cycle? Its also pretty obvious that the premium has turned to a discount and now that discount is widening. This phase has not finished. The trust has a good long-term model but its the wrong time...10 years into an economic recovery, a widening discount on poor performance and a very imprudent bank overdraft. I will keep on my watch list.
14/3/2016
14:25
dr biotech: I am pretty sure that he has all his money invested in either the WPCT or his equity funds. He is doing a live webcast as I type. NEIL WOODFORD says: Today 2:00 pm Kelvin (and others that have asked similar questions), The weakness of the WPCT share price and NAV since the start of 2016 has been the product of the pretty severe sell-off in shares across healthcare, biotech and early-stage quoted stocks, both here in the UK and in the US. Much of this, we believe to be driven by short-term positioning and rotational activity amongst the fund management community. We don’t believe that it is driven by a correction of over-valuation, nor by a deterioration in fundamentals. We remain very pleased with the underlying progress of the businesses in which we have invested in the trust. Indeed, in what has been a pretty short space of time since launch, our expectations for the underlying performance of many businesses in the portfolio have been exceeded. This is a long-term vehicle. We hope to deliver good performance in the short-term but believe we should be judged over the 3 to 5 year time scale we have talked about consistently since launch. Kind regards Neil
Woodford Patient Capital share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171123 05:49:47